Cipla launches Yurpeak® for obesity and type 2 diabetes in India

Cipla Limited has launched Yurpeak® (tirzepatide) in India, a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus. This follows a marketing and distribution agreement with Eli Lilly and Company (India) Private Limited. The launch, announced on December 10, 2025, makes Yurpeak® the second brand of Lilly's tirzepatide available in India.

Yurpeak® is a dual agonist targeting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is indicated as an adjunct to diet and exercise for type 2 diabetes and chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. The therapy will be available in the KwikPen® device in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.

Cipla aims to expand access to tirzepatide across India, leveraging its distribution network. Lilly will manufacture and supply Yurpeak® to Cipla, with pricing aligned to Mounjaro®. Cipla will also provide patient education and support programs covering dosing, self-administration, and safe usage.